The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Medicus Pharma, which trades on the NASDAQ under the ticker MDCX, has announced positive results from an expanded data analysis of its Phase 2 SKNJCT-003 study for basal cell carcinoma. The updated analysis is based on data from 69 patients who strictly met the study's inclusion criteria. The findings demonstrated a clear positive dose-response, supporting the clinical efficacy and safety of its Doxorubicin Microneedle Array (D-MNA) technology. This clinical trial evaluates the treatment's impact on nodular basal cell carcinoma, the most common form of skin cancer. According to the company, these findings provide a strong foundation for the continued clinical development of their disruptive therapeutic asset. This milestone marks a significant step forward in developing non-invasive alternatives for skin cancer patients.
Sign in to access this content
Sign In